Evidence for the use of Levomepromazine for symptom control in the palliative care setting: A systematic review

BMC Palliative Care

Volumn 12, Issue 1, 2013, Pages

  Dietz, Isabel ^a   Schmitz, Andrea ^b   Lampey, Ingrid ^b,c   Schulz, Christian ^b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c NELCS Northeast London (NHS) Community Services   (United Kingdom)

Author keywords

End of life care; Evidence; Levomepromazine; Methotrimeprazine; Palliative care; Symptom control; Systematic review

Indexed keywords

HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; MORPHINE;

ABDOMINAL PAIN; ADVANCED CANCER; BLEEDING; DELIRIUM; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG USE; HUMAN; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; PAIN; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; RETROSPECTIVE MEMORY; REVIEW; SEDATION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84872350496     PISSN: None     EISSN: 1472684X     Source Type: Journal    
DOI: 10.1186/1472-684X-12-2     Document Type: Review

References (78)

1. Symptom burden in the last week of life. Klinkenberg M, Willems DL, van der Wal G, Deeg DJ, J Pain Symptom Manage 2004 27 1 5 13 10.1016/j.jpainsymman. 2003.05.008 14711464 (Pubitemid 38050243)
2. Intensity and treatment of symptoms in 3,030 palliative care patients: a cross-sectional survey of the EAPC Research Network. Laugsand EA, Kaasa S, de Conno F, Hanks G, Klepstad P, J Opioid Manag 2009 5 1 11 21 19344044
3. Symptom prevalence and control during cancer patients' last days of life. Ventafridda V, Ripamonti C, De Conno F, Tamburini M, Cassileth BR, J Palliat Care 1990 6 3 7 11 1704917
4. Care of the dying patient: the last hours or days of life. Ellershaw J, Ward C, BMJ 2003 326 7379 30 34 10.1136/bmj.326.7379.30 12516617 (Pubitemid 36110717)
5. Clinical pathways for care of the dying: an innovation to disseminate clinical excellence. Ellershaw J, J Palliat Med 2002 5 4 617 621 10.1089/109662102760269904 12243687
6. Symptom control during the last week of life on a palliative care unit. Fainsinger R, Miller MJ, Bruera E, Hanson J, Maceachern T, J Palliat Care 1991 7 1 5 11 2045996
7. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Cherny NI, Radbruch L, Palliat Med 2009 23 7 581 593 10.1177/0269216309107024 19858355
8. Levomepromazine for schizophrenia. Sivaraman P, Rattehalli RD, Jayaram MB, Cochrane Database Syst Rev 2010 10 D007779 20927765
9. Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Hals PA, Hall H, Dahl SG, Life Sci 1988 43 5 405 412 10.1016/0024-3205(88)90519-X 2899826
10. Levomepromazine receptor binding profile in human brain-implications for treatment-resistant schizophrenia. Lal S, Nair NP, Cecyre D, Quirion R, Acta Psychiatr Scand 1993 87 6 380 383 10.1111/j.1600-0447.1993.tb03391.x 8395131 (Pubitemid 23186257)
11. NHS, Levomepromazine in Palliative Care http://www.palliativedrugs.com: http://www.palliativecareguidelines.scot.nhs.uk/documents/Levomepromazine.pdf; 2010
12. Nausea and vomiting in advanced cancer. Harris DG, Br Med Bull 2010 96 1 175 185 10.1093/bmb/ldq031 20884654
13. Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Eisenchlas JH, Garrigue N, Junin M, De Simone GG, Palliat Med 2005 19 1 71 75 10.1191/0269216305pm972oa 15690871 (Pubitemid 40202061)
14. Sedation for the care of patients with advanced cancer. Cherny NI, Nat Clin Pract Oncol 2006 3 9 492 500 16955088 (Pubitemid 44340365)
15. Palliative cancer care-nausea & vomiting-Management. Levomepromazine (oral or parenteral) http://www.cks.nhs.uk/palliative-cancer-care-nausea- vomiting/management/quick-answers/scenario-nausea-and-vomiting-management/ prescriptions/levomepromazine-oral-or-parenteral 23498965
16. Palliation of nausea and vomiting in malignancy. Mannix K, Clin Med 2006 6 2 144 147 16688970
17. Pain management and symptom-oriented drug therapy in palliative care. Klein C, Lang U, Bukki J, Sittl R, Ostgathe C, Breast Care 2011 6 1 27 34 10.1159/000324702 21547023
18. Controlling cancer pain. Foley KM, Hosp Pract 2000 35 4 101 112 10.3810/hp.2000.04.193 (Pubitemid 30219969)
19. Antipsychotics for acute and chronic pain in adults. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T, Cochrane Database Syst Rev 2008 4 D004844 18843669
20. Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review. Fonzo-Christe C, Vukasovic C, Wasilewski-Rasca AF, Bonnabry P, Palliat Med 2005 19 3 208 219 10.1191/0269216304pm1006oa 15920935 (Pubitemid 40668080)
21. Sanofi-Aventis, Summary of Product Characteristics: Nozinan 2012 http://www.medicinesorguk/emc/medicine/6603/SPC//Nozinan+injection
22. Palliative Care Formulary. Twycross R, Wilcock A, 2011 4 palliativedrugs.com
23. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. Davis MP, Hallerberg G, J Pain Symptom Manage 2010 39 4 756 767 10.1016/j.jpainsymman.2009.08.010 20413062
24. The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Booth S, Moosavi SH, Higginson IJ, Nature Clinical Practice Oncology 2008 5 2 90 100 10.1038/ncponc1034 18235441 (Pubitemid 351188930)
25. Development of a clinical guideline for palliative sedation therapy using the Delphi method. Morita T, Bito S, Kurihara Y, Uchitomi Y, Journal of Palliative Medicine 2005 8 4 716 729 10.1089/jpm.2005.8.716 16128645 (Pubitemid 41266247)
26. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D, PLoS medicine 2009 6 7 1000100 10.1371/journal.pmed.1000100 19621070
27. Development of a subject search filter to find information relevant to palliative care in the general medical literature. Sladek R, Tieman J, Fazekas BS, Abernethy AP, Currow DC, Journal of the Medical Library Association: JMLA 2006 94 4 394 401 17082830 (Pubitemid 44837815)
28. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M, Oxford Centre for Evidence-based Medicine-Levels of Evidence 2011 http://www.pdptoolkit.co.uk/Files/ebm/cebm/Doing%20ebm/levels-of-evidence.htm
29. EQUATOR Network collates resources for good research. Simera I, BMJ 2008 337 2471 10.1136/bmj.a2471 19001485
30. Case report: Maintaining and withdrawing long-term invasive ventilation in a patient with MND/ALS in a home setting. Lebon B, Fisher S, Palliative Medicine 2011 25 3 262 265 10.1177/0269216310389224 21228095
31. At-home palliative sedation for end-of-life cancer patients. Alonso-Babarro A, Varela-Cerdeira M, Torres-Vigil I, Rodriguez-Barrientos R, Bruera E, Palliative Medicine 2010 24 5 486 492 10.1177/0269216309359996 20133320
32. Seizing the opportunity to consider uncontrollable seizures in the palliative setting. D'Cruz RS, Agar M, Asia-Pacific Journal of Clinical Oncology 2009 5 243
33. The use of sedative drugs at the end of life in a UK hospice. Stephenson J, Palliative Medicine 2008 22 8 969 970 10.1177/0269216308098801 18952744
34. Inappropriateness of using opioids for end-stage palliative sedation: a Dutch study. Reuzel RP, Hasselaar GJ, Vissers KC, van der Wilt GJ, Groenewoud JM, Crul BJ, Palliat Med 2008 22 5 641 646 10.1177/0269216308091867 18612030
35. Sedative use in the last week of life and the implications for end-of-life decision making. Sykes N, Thorns A, Archives of Internal Medicine 2003 163 3 341 344 10.1001/archinte.163.3.341 12578515 (Pubitemid 36183863)
36. Agitation and restlessness in the last 24 hours of life on the Liverpool care pathway for the dying patient (LCP). Gambles M, McGlinchey T, Dickman A, Ellershaw JE, Murphy D, Palliative Medicine 2010 1 70
37. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. Morita T, Tsunoda J, Inoue S, Chihara S, Journal of Pain and Symptom Management 2001 21 4 282 289 10.1016/S0885-3924(01)00258-5 11312042 (Pubitemid 32331881)
38. A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Fainsinger RL, Waller A, Bercovici M, Bengston K, Landman W, Hosking M, Nunez-Olarte JM, de Moissac D, Palliative Medicine 2000 14 4 257 265 10.1191/026921600666097479 10974977 (Pubitemid 30609544)
39. Sedation for intractable distress in the dying-A survey of experts. Chater S, Viola R, Paterson J, Jarvis V, Palliative Medicine 1998 12 4 255 269 10.1191/026921698671831786 9743824 (Pubitemid 28344639)
40. A comparison of the use of sedatives in a hospital support team and in a hospice. Stone P, Phillips C, Spruyt O, Waight C, Palliat Med 1997 11 2 140 144 10.1177/026921639701100208 9156110 (Pubitemid 27170619)
41. The use of methotrimeprazine in terminal care. Oliver DJ, The British journal of clinical practice 1985 39 9 339 340 4063129
42. Palliative sedation in patients with advanced cancer followed at home: a systematic review. Mercadante S, Porzio G, Valle A, Fusco F, Aielli F, Costanzo V, Journal of Pain and Symptom Management 2011 41 4 754 760 10.1016/j. jpainsymman.2010.07.013 21227633
43. Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. De Graeff A, Dean M, Journal of Palliative Medicine 2007 10 1 67 85 10.1089/jpm.2006.0139 17298256 (Pubitemid 46238955)
44. Ethical validity of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. Morita T, Chinone Y, Ikenaga M, Miyoshi M, Nakaho T, Nishitateno K, Sakonji M, Shima Y, Suenaga K, Takigawa C, Journal of Pain and Symptom Management 2005 30 4 308 319 10.1016/j.jpainsymman.2005.03.016 16256895 (Pubitemid 41527117)
45. Terminal sedation in palliative medicine definition and review of the literature. Cowan JD, Walsh D, Supportive Care in Cancer 2001 9 6 403 407 10.1007/s005200100235 11585266 (Pubitemid 32843627)
46. The use of opioids and sedatives at the end of life. Sykes N, Thorns A, Lancet Oncology 2003 4 5 312 318 10.1016/S1470-2045(03)01079-9 12732169 (Pubitemid 36592499)
47. Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice. Molassiotis A, Brearley SG, Stamataki Z, Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 2011 19 7 949 956 10.1007/s00520-010-0909-7
48. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Stephenson J, Davies A, Supportive Care in Cancer 2006 14 4 348 353 10.1007/s00520-005-0897-1 16228185
49. High-dose levomepromazine (methotrimeprazine) to control nausea in carcinoid syndrome. Amesbury B, Alloway L, Hickmore E, Dewhurst G, Journal of Palliative Care 2004 20 2 117 118 15332477 (Pubitemid 38952268)
50. An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Kennett A, Hardy J, Shah S, A'Hern R, Supportive Care in Cancer 2005 13 9 715 721 10.1007/s00520-004-0768-1 15700129 (Pubitemid 41435563)
51. Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy. Higi M, Niederle N, Bierbaum W, Schmidt CG, Seeber S, Journal of cancer research and clinical oncology 1980 97 1 81 86 10.1007/BF00411281 7190568 (Pubitemid 10100493)
52. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M, Supportive Care in Cancer 2004 12 6 432 440 10.1007/s00520-004-0629-y 15108099 (Pubitemid 38797099)
53. Unlicensed uses for medication in a palliative care unit. Atkinson CV, Kirkham SR, Palliative Medicine 1999 13 2 145 152 10.1191/026921699676057177 10474697 (Pubitemid 29171395)
54. Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. Douglas C, Murtagh FE, Chambers EJ, Howse M, Ellershaw J, Palliat Med 2009 23 2 103 110 10.1177/0269216308100247 19273566
55. The use of low-dose methotrimeprazine (levomepromazine) in the management of nausea and vomiting. Twycross R, Bankby G, Hallowood J, Prog Palliat Care 1997 5 49 53
56. Management of insomnia in patients with chronic pain conditions. Stiefel F, Stagno D, CNS Drugs 2004 18 5 285 296 10.2165/00023210-200418050-00002 15089114 (Pubitemid 38526713)
57. Treatment of terminal restlessness: A review of the evidence. Kehl KA, Journal of Pain and Palliative Care Pharmacotherapy 2004 18 1 5 30 15364628 (Pubitemid 38747715)
58. Treatment of delirium in a terminally ill patient. Fainsinger R, Bruera E, Journal of Pain and Symptom Management 1992 7 1 54 56 10.1016/0885-3924(92) 90108-T 1538182
59. The use of methotrimeprazine (Levoprome) in a patient sensitive to opioids and possible bowel shutdown. Rogers AG, J Pain Symptom Manage 1989 4 1 44 45 10.1016/0885-3924(89)90065-1 2703737 (Pubitemid 19093480)
60. Levomepromazine-induced lupus? Fletcher AJ, J Pain Symptom Manage 2009 37 6
61. Current Practice in the Management of Terminal Haemorrhage by Palliative Care Teams in the UK. Harris DG, Palliat Med (Abstracts of EAPC (European Association for Palliative Care) 2010 24 4 Suppl 5 229
62. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, PLoS medicine 2007 4 10 297 10.1371/journal.pmed.0040297 17941715 (Pubitemid 350035454)
63. Instructions to authors for case reporting are limited: a review of a core journal list. Sorinola O, Olufowobi O, Coomarasamy A, Khan KS, BMC medical education 2004 4 4 10.1186/1472-6920-4-4 15043755
64. Good practice in the conduct and reporting of survey research. Kelley K, Clark B, Brown V, Sitzia J, International journal for quality in health carez: journal of the International Society for Quality in Health Care / ISQua 2003 15 3 261 266 10.1093/intqhc/mzg031 (Pubitemid 36675722)
65. Treatment of nausea and vomiting in terminally ill cancer patients. Glare PA, Dunwoodie D, Clark K, Ward A, Yates P, Ryan S, Hardy JR, Drugs 2008 68 18 2575 2590 10.2165/0003495-200868180-00004 19093700
66. Treating nausea and vomiting in palliative care: a review. Glare P, Miller J, Nikolova T, Tickoo R, Clinical interventions in aging 2011 6 243 259 21966219
67. Darvill E, Dorman S, Perkins P, Levomepromazine for nausea and vomiting in palliative care In: Cochrane Protocol. Cochrane Database 2012
68. ABC of palliative care. The last 48 hours. Adam J, British Medical Journal 1997 315 7122 1600 1603 10.1136/bmj.315.7122.1600 9437282 (Pubitemid 27522406)
69. Sedation in palliative care. Vissers KCP, Hasselaar J, Verhagen SAHHVM, Current Opinion in Anaesthesiology 2007 20 2 137 142 10.1097/ACO. 0b013e328049557b 17413397 (Pubitemid 46594849)
70. Palliating delirium in patients with cancer. Caraceni A, Simonetti F, The Lancet Oncology 2009 10 2 164 172 10.1016/S1470-2045(09)70018-X 19185834
71. Pharmacological approaches other than opioids in chronic non-cancer pain management. Merskey H, Acta anaesthesiologica Scandinavica 1997 41 1 Pt 2 187 190 9061105 (Pubitemid 27072925)
72. Methotrimeprazine: a new phenothiazine derivative with analgesic properties. Lasagna L, Dekornfeld TJ, JAMA: the journal of the American Medical Association 1961 178 887 890 10.1001/jama.1961.03040480017004
73. A comparison of the analgesic effects of methotrimeprazine and morphine in patients with cancer. Beaver WT, Wallenstein SL, Houde RW, Rogers A, Clinical pharmacology and therapeutics 1966 7 4 436 446 5328470
74. Analgesic treatment with levomepromazine in acute myocardial infarction. Davidsen O, Lindeneg O, Walsh M, A randomized clinical trial. Acta medica Scandinavica 1979 205 3 191 194 (Pubitemid 9137346)
75. Comparative Analgesic Activity of Levomepromazine and Morphine in Patients with Chronic Pain. Bloomfield S, Simard-Savoie S, Bernier J, Tetreault L, Canadian Medical Association journal 1964 90 1156 1159 14145469
76. End of life care in patients with malignant disease. Stone P, Rees E, Hardy JR, Eur J Cancer 2001 37 9 1070 1075 10.1016/S0959-8049(01)00087-9 11378335 (Pubitemid 32520878)
77. Why are trials in palliative care so difficult? Grande GE, Todd CJ, Palliat Med 2000 14 1 69 74 10.1191/026921600677940614 10717728 (Pubitemid 30095231)
78. Randomized controlled trials in palliative care: overcoming the obstacles. Hudson P, Aranda S, McMurray N, International journal of palliative nursing 2001 7 9 427 434 11832846